Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity
- PMID: 33257802
- PMCID: PMC8452716
- DOI: 10.1038/s41433-020-01321-z
Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity
Abstract
Background/objectives: The prevalence of myopia is higher in preterm infants who underwent laser photocoagulation (LPC) for retinopathy of prematurity (ROP). The aim of this study was to investigate factors associated with myopia in preterm infants who undergo LPC for ROP.
Subjects/methods: We retrospectively analysed the medical records of preterm infants born at Kyushu University Hospital (October 2008-March 2018) at ≤32 weeks of gestational age or with birth weight ≤1500 g. We evaluated the associations between nine clinical factors and the spherical equivalent at 1-year corrected age by performing multivariable linear regression in LPC-treated ROP patients.
Results: Among the 485 infants enroled, 76 developed ROP requiring treatment. Of these, 71 underwent LPC, which was provided to 63 infants as the primary treatment (LPC alone or the combination therapy of LPC and intravitreal injection of bevacizumab [IVB]) and to eight infants as additional LPC after IVB monotherapy. The results of a refractive examination at 1-year corrected age were available for 110 eyes of 56 infants (78.9%). The mean ± standard deviation of the SE value was -0.5 ± 3.0 dioptres (D). Multivariable linear regression analysis revealed a significant association between laser spot count and SE value (ß = -0.081 ± 0.040 D per 100 spots [mean ± standard error], p = 0.045).
Conclusions: Our results suggest that an increased laser spot count observed during ROP treatment associates with myopia.
© 2020. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures


Similar articles
-
Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?Int Ophthalmol. 2023 May;43(5):1453-1458. doi: 10.1007/s10792-022-02540-x. Epub 2022 Sep 23. Int Ophthalmol. 2023. PMID: 36149616
-
One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.Int Ophthalmol. 2023 Jul;43(7):2197-2202. doi: 10.1007/s10792-022-02615-9. Epub 2022 Dec 15. Int Ophthalmol. 2023. PMID: 36522564
-
Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Curr Eye Res. 2017 Mar;42(3):462-469. doi: 10.1080/02713683.2016.1196709. Epub 2016 Jul 15. Curr Eye Res. 2017. PMID: 27420302
-
Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.PLoS One. 2019 Dec 2;14(12):e0225643. doi: 10.1371/journal.pone.0225643. eCollection 2019. PLoS One. 2019. PMID: 31790445 Free PMC article.
-
Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes.Surv Ophthalmol. 2021 Jul-Aug;66(4):572-584. doi: 10.1016/j.survophthal.2020.12.002. Epub 2020 Dec 16. Surv Ophthalmol. 2021. PMID: 33338470 Review.
Cited by
-
Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab.Indian J Ophthalmol. 2022 Oct;70(10):3584-3590. doi: 10.4103/ijo.IJO_243_22. Indian J Ophthalmol. 2022. PMID: 36190051 Free PMC article.
-
Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.Am J Ophthalmol. 2022 Aug;240:252-259. doi: 10.1016/j.ajo.2022.03.020. Epub 2022 Mar 31. Am J Ophthalmol. 2022. PMID: 35367438 Free PMC article.
-
Association between myopia progression and quantity of laser treatment for retinopathy of prematurity.PLoS One. 2022 Dec 30;17(12):e0279898. doi: 10.1371/journal.pone.0279898. eCollection 2022. PLoS One. 2022. PMID: 36584135 Free PMC article.
-
Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity.Int J Ophthalmol. 2022 May 18;15(5):753-759. doi: 10.18240/ijo.2022.05.10. eCollection 2022. Int J Ophthalmol. 2022. PMID: 35601165 Free PMC article.
-
Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?Int Ophthalmol. 2023 May;43(5):1453-1458. doi: 10.1007/s10792-022-02540-x. Epub 2022 Sep 23. Int Ophthalmol. 2023. PMID: 36149616
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources